Drug
Cefiderocol clinical trials
Also written Fetroja and S-649266.
- studies test it
- 18
- open now
- 4
- in phase 3
- 3
- first study started
- 2015
Keep track of what changes. Save the Cefiderocol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
18 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 5
- Phase 3
- 3
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 8
Shionogi (8) · Qpex Biopharma, Inc. (2) · Hartford Hospital (2) · Joseph L. Kuti, PharmD (1) · The University of Queensland (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · University of Tennessee (1) · Rambam Health Care Campus (1)
Often tested with
Tested in the same studies.
Xeruborbactam (2) · Avibactam, ceftazidime drug combination (2) · Meropenem and vaborbactam (2) · Aztreonam (2) · Eravacycline (2) · Tigecycline (2) · Midazolam (1) · Imipenem (1)
Studies
Open first, then newest update. How each study uses Cefiderocol is read from its arms, and is right about nine times in ten.
Testing it · 18
- Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver TransplantationNot yet recruitingPhase 3IRCCS Azienda Ospedaliero-Universitaria di BolognaNCT07759453Written as Cefiderocol
- Pharmacokinetic Analysis of Cefiderocol in Patients With Acute Burn InjuriesRecruitingPhase 4University of TennesseeNCT07465432Written as Cefiderocol
- Cefiderocol and Ampicillin-sulbactam vs. Colistin +/- Meropenem for Carbapenem Resistant A. BaumanniiRecruitingPhase 4Rambam Health Care CampusNCT05922124Written as Cefiderocol
- Optimising TREATment for Severe Gram-Negative Bacterial InfectionsRecruitingPhase 4National University of SingaporeNCT07004049Written as Cefiderocol
- A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal ImpairmentCompletedPhase 1Qpex Biopharma, Inc.NCT07104162Written as Cefiderocol/Xeruborbactam
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and InfantsCompletedPhase 2ShionogiNCT06086626Written as Cefiderocol
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric ParticipantsCompletedPhase 2ShionogiNCT04335539Written as Cefiderocol
- A DDI Study to Investigate PK and Safety of Cefiderocol in Combination With Xeruborbactam in Healthy Adult ParticipantsCompletedPhase 1Qpex Biopharma, Inc.NCT06547554Written as Cefiderocol
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric ParticipantsCompletedPhase 2ShionogiNCT04215991Written as Cefiderocol
- Cefiderocol Plasma Concentrations in Patients Receiving Renal Replacement TherapyCompletedPhase 1Hartford HospitalNCT05373615Written as Cefiderocol
- Cefiderocol PK in Patients on ECMOCompletedPhase 1Joseph L. Kuti, PharmDNCT04995835Written as Cefiderocol
- Cefiderocol Pharmacokinetics in Adult Patients With Cystic FibrosisCompletedPhase 4Hartford HospitalNCT05314764Written as Cefiderocol
- RCT Cefiderocol vs BAT for Treatment of Gram Negative BSICompletedPhase 2The University of QueenslandNCT03869437Written as Cefiderocol
- A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsCompletedPhase 1ShionogiNCT05395104Written as Cefiderocol
- Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative PathogensCompletedPhase 3ShionogiNCT02714595Written as Cefiderocol
- Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative PathogensCompletedPhase 3ShionogiNCT03032380Written as Cefiderocol
- Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial PneumoniaTerminatedPhase 1ShionogiNCT03862040Written as Cefiderocol
- A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract InfectionsCompletedPhase 2ShionogiNCT02321800Written as Cefiderocol
Codes
What other systems call Cefiderocol · ClinicalTrials.gg INT006877
- MeSH (NLM) D000097602CefiderocolConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) SZ34OMG6E8CEFIDEROCOLConfirmed FDA, NLM, Wikidata
- RxNorm 2265702Confirmed FDA, Wikidata
- Wikidata Q27289472cefiderocolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169831CefiderocolOne source FDA
- DrugBank DB14879One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000097602 | Cefiderocol | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | SZ34OMG6E8 | CEFIDEROCOL | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2265702 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27289472 | cefiderocol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169831 | Cefiderocol | One source FDA |
| DrugBank | DB14879 | — | One source Wikidata |
Also registered as cefiderocol sulfate tosylate (UNII TTP8LBP45D · RxNorm 2265863).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.